Drug Trial News

RSS

HOOKVAC consortium to begin first clinical testing of human hookworm vaccine in West Africa

The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership's (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world's poorest people.

27 Sep 2013

Center of Reproductive Medicine announces participation in Thrive-IVF Research Study

The Center of Reproductive Medicine today announced its participation in the Thrive-IVF Research Study, a Phase 2 clinical trial sponsored by Nora Therapeutics, Inc., to evaluate the efficacy, safety and tolerability of NT100 in women who have had repeated in vitro fertilization (IVF) failures despite having good quality embryos.

26 Sep 2013

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome. The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S.

26 Sep 2013

Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the European Society for Medical Oncology 2013 annual meeting in Amsterdam.

26 Sep 2013

Sulfasalazine drug does not reduce diarrhea for patients receiving pelvic radiation therapy: Study

Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area a Mayo Clinic-led study has found.

24 Sep 2013

Rhythm starts RM-493 clinical trials in obesity patients with genetic deficiency

Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.

24 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

A drug formerly used to treat the skin disorder psoriasis has shown encouraging results in a phase 2 trial to assess its effectiveness in treating type 1 diabetes, according to new research published in The Lancet Diabetes & Endocrinology.

24 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen.

21 Sep 2013

Equatorial Guinea presents design for malaria vaccine trial

Equatorial Guinea's Ministry of Health and Social Security recently presented a design for a malaria vaccine trial as part of the government's efforts to improve the country's public health.

21 Sep 2013

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy, show that most SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests up to 14 months after a single injection of the drug.

19 Sep 2013

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

19 Sep 2013

First clinical trials to diagnose and treat Alzheimer’s disease

More than a century ago, Alois Alzheimer, a Bavarian physician, first identified the neurodegenerative brain condition that came to be known as Alzheimer's disease. Finding ways to diagnose and treat this disease has frustrated scientists and clinicians ever since.

19 Sep 2013

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Results of a Pfizer-commissioned study published this month in Annals of Internal Medicine reveal that smokers with a past or present diagnosis of major depressive disorder (MDD)* taking varenicline had a significantly higher likelihood of quitting smoking (after 12 weeks and at 52 weeks) than those who were given a placebo.

18 Sep 2013

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis.

18 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

Intra-articular hyaluronic acid injections safe, effective for patients with knee osteoarthritis

A new meta-analysis of 29 randomized studies involving more than 4,500 patients with knee osteoarthritis found that intra-articular hyaluronic acid injections provided significant improvement in pain and function compared to saline injections.

18 Sep 2013

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients.

18 Sep 2013

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.

17 Sep 2013

Drug Trial News

HOOKVAC consortium to begin first clinical testing of human hookworm vaccine in West Africa

Center of Reproductive Medicine announces participation in Thrive-IVF Research Study

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

Sulfasalazine drug does not reduce diarrhea for patients receiving pelvic radiation therapy: Study

Rhythm starts RM-493 clinical trials in obesity patients with genetic deficiency

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

Equatorial Guinea presents design for malaria vaccine trial

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

First clinical trials to diagnose and treat Alzheimer’s disease

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

Intra-articular hyaluronic acid injections safe, effective for patients with knee osteoarthritis

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News